ライフサイエンスコーパス: kg

1 t diabetes, aged 18-60 y, with BMI 20.0-30.0 kg/m2 who were unrestrained eaters participated in a dou

2 t 18 months, PLWH on dolutegravir gained 6.0 kg, compared to 2.6 kg for NNRTIs (P < .05), and 0.5 kg

3 act of PCG managed with different N rates [0 kg N ha(-1) (PCG-0N), 75 kg N ha(-1) (PCG-75N), 150 kg N

4 improvements than the C + Ex in arm LM (0.07 kg; 95% CI: 0.01, 0.14; P = 0.029), gait speed (0.05 m/s

5 ure body mass index (BMI) was 46.01 +/- 4.07 kg/m with a postsleeve gastrectomy BMI of 34.07 +/- 3.73

6 neonates had decreased ponderal index (-0.09 kg/m3, 95% CI -0.17 to -0.01, p = 0.03) versus glyburide

7 on intensity from 2.4 +/- 0.1 to 1.6 +/- 0.1 kg CO(2) eq per kg milk, FeCo reduced it to 2.2 +/- 0.1,

8 mean weight 37.2+/-27.5 kg (range, 1.7-149.1 kg).

9 Seven anesthetized pigs 28.7 kg (SD, 2.1 kg).

10 years (SD 10.8), body mass index (BMI) 27.1 kg/m2 (SD 4.7).

11 ng male rhesus monkeys (~1-2 y old, ~3 +/- 1 kg).

12 ifference (95% confidence interval, CI) -3.1 kg/m (-4.4 to -1.9) kg/m, P < 0.001] and HbA1c change [m

13 e: 50 +/- 2 years: body mass index: 31 +/- 1 kg m(-2) ) received primed continuous l-[ring-(2) H(5) ]

14 ompared to raltegravir (3.4 kg) and PIs (4.1 kg), though these differences were not statistically sig

15 (reduction in body mass index of 6.3 +/- 4.1 kg/m(2) in patients with persistent NASH vs reduction of

16 A 1-kg/m(2) increase in body mass index was associated with

17 decreasing by 12% (95% CI, .81%-.95%) per 1-kg increase.

18 ifference (95% CI): 266 (77, 455) nmol.min-1.kg-1.180 min; P = 0.01; eta2p = 0.44].

19 rence (95% CI): 4266 (261, 8270) mumol.min-1.kg-1.180 min; P = 0.04; eta2p = 0.31] and branched-chain

20 independent acquisitions of very large (>100 kg) body size within Vombatiformes, several having alrea

21 e cardiac ICU who received fluid bolus (10mL/kg of Ringers-Lactate over 30 min) for management of sho

22 Subjects with ARDS and obesity (BMI=57+/-12 kg/m(2)), following LRM, required an increase in PEEP of

23 study, a stable nitrogen removal rate (0.13 kg m(-3) day(-1)), together with a high-level effluent q

24 to enable and accelerate KT in children <=15 kg based on the establishment of one specialized transpl

25 release between 8.7 x 10(13) to 5.0 x 10(15) kg of H(2)O vapour instantaneously into the atmosphere.

26 (-1) (PCG-0N), 75 kg N ha(-1) (PCG-75N), 150 kg N ha(-1) (PCG-150N), and 225 kg N ha(-1) (PCG-255N)],

27 or different nitrogen (N) inputs (0, 80, 160 kg N/ha) for five environments in SSA, including cool su

28 N ha(-1) in urea) and high N input (HN: 168 kg N ha(-1) in urea).

29 ain, a loading equivalent to 44 000 +/- 1700 kg y(-1) of lens dry mass discharged into US wastewater.

30 Olcegepant (1mg/kg, single dose) increased infarct risk after 12- to 20-

31 , whereas FoFeCo increased it to 2.7 +/- 0.2 kg CO(2) eq per kg milk because of land use change emiss

32 n 11 healthy males (28 +/- 7 years; 23 +/- 2 kg m(-2) ), FMD (Duplex ultrasound), arterial blood gase

33 e: 56 +/- 5 years: body mass index: 32 +/- 2 kg m(-2) ) and non-diseased controls (age: 50 +/- 2 year

34 (2)peak responders (ie, Delta >=1.32 mL O(2).kg(-1).min(-1)).

35 amounts of CO(2) (147-424 g equivalent CO(2)/kg ash).

36 body weight (dose area product/kg; uGy*m(2)/kg) and reported by expected radiation exposure categori

37 h < 0.23% water and a high (>1,000 mmol O(2)/kg lipid hydroperoxides after 4 weeks) in gels with > 2.

38 Lipid oxidation was low (~30 mmol O(2)/kg lipid hydroperoxides after 6 weeks) in gels with < 0.

39 (HR 1.047, p = 0.006), body mass index < 20 kg/m(2) at the time of gastrostomy placement (HR 2.012,

40 t ruminally cannulated Holstein heifers (200 kg) were used in a factorial, repeated measures experime

41 icular LM in the per-protocol analysis (0.21 kg; 95% CI: 0.02, 0.40; P = 0.03).

42 fe cycle, yet light enough (approximately 21 kg when filled with soil) for routine handling.

43 (aHR, 1.04; P < 0.001), body mass index <21 kg/m (aHR, 1.61; P = 0.006), and HCV (aHR, 1.83; P < 0.0

44 CG-75N), 150 kg N ha(-1) (PCG-150N), and 225 kg N ha(-1) (PCG-255N)], and PCG intercropped with KC (P

45 n age at ITx was 7.7 years and weight was 23 kg.

46 egining of pregnancy (mean difference: -1.24 kg; 95% CI: -2.18, -0.30; P for interaction < 0.05).

47 attenuation parameters < 296 dB/m, BMI < 25 kg/m(2) and normal waist circumference were included in

48 In children weighing 25 kg to less than 40 kg, we also assessed dolutegravir pha

49 Addition of 0.25mg/kg PQ was associated with near complete prevention of tr

50 adults with a body mass index (BMI) of 19-27 kg/m(2).(10-18) Twelve healthy adults (age: 26.3 +/- 3.4

51 unteers (35 controls [body mass index 24+/-3 kg/m(2)], 45 obese [body mass index 35+/-5 kg/m(2)]) wit

52 usted for baseline weight and group, was 3.3 kg (95% CI 1.9, 4.8) in favour of the intervention group

53 ding to a space time yield of about 30x10(3) kg m(-3) day(-1) , which is 1-2 orders of magnitude grea

54 index (BMI) as a marker of obesity (BMI > 30 kg/m(2)).

55 Obesity (BMI > 30 kg/m2) was more prevalent in the class Diet (41.2%, 95%

56 ran Africa, and 12.6% were obese (BMI > = 30 kg/m(2)).

57 fect on obesity (body mass index [BMI] >= 30 kg/m2) in >450,000 individuals (age 40-69 years) of the

58 del showed that non-obese patients (BMI < 30 kg/m(2)) were at significantly reduced risk for perioper

59 rty-one overweight men and women (BMI: 27-35 kg/m2; aged 40-70 y) completed the study.

60 ): age 44.6 yrs (13.0), body mass index 25.4 kg/m2 (3.6), 60.1% females] without diabetes, hypertensi

61 D4+ T-cell count 512 cells/muL, and BMI 26.4 kg/m2.

62 ht at 18 months compared to raltegravir (3.4 kg) and PIs (4.1 kg), though these differences were not

63 individuals with obesity (BMI: 34.6 +/- 3.4 kg/m2; age: 45.4 +/- 8.2 y; 33 men) enrolled in a 1000-k

64 persistent NASH vs reduction of 13.4 +/- 7.4 kg/m(2); P = .017 with resolution of NASH).

65 In children weighing 25 kg to less than 40 kg, we also assessed dolutegravir pharmacokinetics withi

66 dian age 47 years; median body mass index 46 kg/m).

67 mprovement in weight (mean difference, -2.47 kg; 95% CI, -4.01 to -0.92; P = 0.002).

68 n = 130; M age = 45.8, SD = 8; M BMI = 34.48 kg/m2, SD = 4.87) and randomised by a blinded researcher

69 ared to 2.6 kg for NNRTIs (P < .05), and 0.5 kg for elvitegravir (P < .05).

70 9 days to 18 years), mean weight 37.2+/-27.5 kg (range, 1.7-149.1 kg).

71 ossbred bucks (7-10 months old; 26.5 +/- 3.5 kg, BW).

72 3 kg/m(2)], 45 obese [body mass index 35+/-5 kg/m(2)]) without coexisting cardiovascular disease.

73 3.9] and 16.7 [6.8-29.7] mg/dL) and those <5 kg (2.6 [1.8-3.4] and 13.5 [3.0-28.4] mg/dL).

74 h the traditional pathway features (OR per 5 kg/m2: 1.73; 95% CI: 1.28, 2.34; Pheterogeneity = 0.01).

75 y(vinyl ethers) of molar masses exceeding 50 kg mol(-1) can be produced within 1 h without elaborate

76 duction in fat mass (mean difference, -1.537 kg; 95% CI, -2.947 to -0.127; P = 0.033), and improvemen

77 Obese subjects (body mass index 35 to 55 kg/m(2)) were randomized 1:1 to either sham or TBE targe

78 that intermediate-sized herbivores (100-550 kg) switch activity to hotter times of the day when expo

79 raged source rates ranging from 2320 to 5850 kg h(-1) for the three coal mine vents, with 40-45% prec

80 Participants lost, on average, 12 +/- 2.6 kg and regained 52% +/- 38% and 89% +/- 54% of their ini

81 dolutegravir gained 6.0 kg, compared to 2.6 kg for NNRTIs (P < .05), and 0.5 kg for elvitegravir (P

82 ased on a fertilizer application rate of 600 kg N ha(-1) and were in the order AN+ >> FN+ > AN.

83 ) and a N-fertilized treatment receiving 670 kg N ha(-1).

84 levels of application (0, 168, 336, and 672 kg N/ha) were used and replicated three times.

85 (age: 26.3 +/- 3.4 years; BMI: 21.9 +/- 1.7 kg/m(2); 5 females) participated in a randomized crossov

86 Seven anesthetized pigs 28.7 kg (SD, 2.1 kg).

87 .67%), an increase in body mass index (+0.73 kg/m(2)), and a decrease in intravenous antibiotic cours

88 postsleeve gastrectomy BMI of 34.07 +/- 3.73 kg/m, representing total body weight loss of 25.13 +/- 4

89 ifferent N rates [0 kg N ha(-1) (PCG-0N), 75 kg N ha(-1) (PCG-75N), 150 kg N ha(-1) (PCG-150N), and 2

90 ypes analyzed, TW ranged from 73.75 to 79.83 kg/hL.

91 ts were no N input (NN), low N input (LN: 84 kg N ha(-1) in urea) and high N input (HN: 168 kg N ha(-

92 muL (447-935), and body-mass index was 28.9 kg/m(2) (24.0-32.9).

93 body mass index (BMI) between 30.0 and 39.9 kg/m(2) were randomly assigned (1:1 ratio).

94 dence interval, CI) -3.1 kg/m (-4.4 to -1.9) kg/m, P < 0.001] and HbA1c change [mean adjusted differe

95 A total of 171 overweight women [BMI (kg/m2): 28.3 +/- 1.3; age: 35.2 +/- 6.3 y; 88 whites and

96 (3.7 g kg(-1)) than that under PCG-0N (3.2 g kg(-1)) and PCG-75N (3.3 g kg(-1)), respectively.

97 der PCG-0N (3.2 g kg(-1)) and PCG-75N (3.3 g kg(-1)), respectively.

98 ns were identified in powders (18.1 - 35.4 g kg(-1) dry matter).

99 was 15%% and 13% higher under PCG-KC (3.7 g kg(-1)) than that under PCG-0N (3.2 g kg(-1)) and PCG-75

100 a higher intake for older adults (1.0-1.2 g/kg BW/d).

101 increase was significantly less in the 0.7 g/kg/d ethanol group.

102 rotein intake recommendations advise >=0.8 g/kg body weight (BW)/d, whereas experts propose a higher

103 LC3B was significantly reduced in the 2.8 g/kg/d ethanol group.

104 significantly greater in both 0.7 and 2.8 g/kg/d ethanol groups.

105 ree groups and gavage fed with 0.7 and 2.8 g/kg/day ethanol or volume-matched water daily for 8 weeks

106 an extremely high energy density of 27.5 W h kg(-1), which is among that of state-of-the-art stretcha

107 hat Zr-MOF-808 can produce up to 8.66 L(H2O) kg(-1)(MOF) day(-1), an extraordinary finding that outpe

108 tudy 1 [mean +/- SD age: 24 +/- 4 y; BMI (in kg/m2): 22 +/- 2] and 20 in study 2 (mean +/- SD age: 23

109 ude mice were administered 0, 50, or 600 kBq/kg (223)RaCl(2) to create bystander conditions.

110 hazard when 20% versus 10% of a fixed 15 kJ kg(-1) d(-1) PAEE volume was from MVPA).

111 le to deliver a power density of up to 16 kW kg(-1) and an energy density of up to 73 Wh kg(-1) , whi

112 es lower electric-power consumption (1.1 kWh kg(-1) MCCA oil) than membrane electrolysis in series wi

113 trolysis in series with pertraction (9.9 kWh kg(-1) MCCA oil).

114 tors (BCFs) of diclofenac were 0.5 and 3.2 L kg(ww)(-1) in H. azteca and G. pulex, respectively, wher

115 as BCFs of DCF-M310.03 was 164.5 and 104.7 L kg(ww)(-1), respectively, representing a 25- to 110-fold

116 SUVs remain stable down to 1/3 dose (1.2 MBq/kg).

117 ecific methanol formation rate of 524 g(MeOH)kg(cat)(-1)h(-1) at 220 degrees C, 3.3 times higher than

118 traditional Cu/ZrO(2) catalysts (159 g(MeOH)kg(cat)(-1)h(-1)).

119 y; n=90) or lower-dose (LD-NaHCO(3); 0.5 meq/kg of lean body wt per day; n=52) NaHCO(3) or matching p

120 to receive higher-dose (HD-NaHCO(3); 0.8 meq/kg of lean body wt per day; n=90) or lower-dose (LD-NaHC

121 0.9997 (concentration range: 0.05 and 2.0 mg kg(-1)).

122 very potency in vivo at a low dose of 0.1 mg kg(-1) when formulated with a PBD-lipid containing a BOD

123 pyram, spinosad or cyprodinil (0.006-0.22 mg kg(-1)).

124 -2900.00, 3800.00-5200.00 and 51.33-61.28 mg kg(-1) respectively.

125 , phosphorus content ranged from 7 to 600 mg kg(-1) soil, and the relative abundance of arbuscular my

126 early pregnancy was determined to be 15 mg . kg-1 . d-1 (95% CI: 10.4, 19.9 mg . kg-1 . d-1); during

127 g-1 . d-1) and IAAO (95% CI: 10.5, 32.2 mg . kg-1 . d-1).

128 e pregnancy, it was determined to be 21 mg . kg-1 . d-1 by DAAO (95% CI: 17.4, 24.7 mg . kg-1 . d-1)

129 kg-1 . d-1 by DAAO (95% CI: 17.4, 24.7 mg . kg-1 . d-1) and IAAO (95% CI: 10.5, 32.2 mg . kg-1 . d-1

130 15 mg . kg-1 . d-1 (95% CI: 10.4, 19.9 mg . kg-1 . d-1); during late pregnancy, it was determined to

131 mg.kg(-1)) than in leaves (1477.7-8709.0 mg.kg(-1)).

132 erries was considerably lower (76.1-205.2 mg.kg(-1)) than in leaves (1477.7-8709.0 mg.kg(-1)).

133 n of the selective agonist imiquimod (5.0 mg/kg) induces a phenotype in offspring characterized by re

134 after 24 weeks of treatment at 2.0 or 6.0 mg/kg/day.

135 lution available ad libitum (39.25-266.00 mg/kg).

136 7) or the active control midazolam (0.025 mg/kg, N=23), provided during the second week of a 5-week o

137 ceptor antagonist naltrexone (0.001-0.032 mg/kg) was injected prior to test sessions to evaluate acut

138 Terpenes (15.57-41.05 mg/kg), accounting for ~97% of total volatiles, were associ

139 calculated as 0.07 mg/kg (as Co) and 0.06 mg/kg, respectively.

140 LC-ICP-OES system were calculated as 0.07 mg/kg (as Co) and 0.06 mg/kg, respectively.

141 0-min after double-blind injection of .08 mg/kg morphine or placebo.

142 -pinene as the main volatile (14.47-37.09 mg/kg).

143 Performance at 0.1 mg/kg clozapine and 0.1 mg/kg deschloroclozapine did not di

144 erformance at 0.1 mg/kg clozapine and 0.1 mg/kg deschloroclozapine did not differ from vehicle in any

145 Two of 6 patients treated at 1 mg/kg experienced dose-limiting toxicity (DLT) from immune-

146 Two monkeys were impaired after 0.1 mg/kg olanzapine and two were impaired after 0.3 mg/kg desc

147 cid (33.4%) and total tocopherols (2540.1 mg/kg).

148 Isoprenaline (Iso, 1 mg/kg, sc., 10 days) was administered 5 weeks after Px with

149 N3-ABD-T20-mediated tumor regression at 1 mg/kg.

150 At the dose of 10 mg/kg (600 mg for flat-dosing), flat-dosing resulted in hig

151 nterferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10).

152 e treated: three received margetuximab 10 mg/kg intravenously plus pembrolizumab 200 mg intravenously

153 /kg cyclosporine A and received either 10 mg/kg prednisolone (P), or LP intravenously on day 0, 3, an

154 5 mM LiCl in sucrose solution (6.50-40.10 mg/kg) or had the same solution available ad libitum (39.25

155 ith higher cumulative steroid use (per 10 mg/kg) were at greatest risk.

156 3 weeks or six cycles of bevacizumab (10 mg/kg, days 1 and 15) plus carboplatin (AUC 5, day 1) plus

157 a peripheral vessel in the right arm (10 mg/kg, providing therapeutic-level antibody concentrations)

158 prominent and of shortest latency with 10 mg/kg/d GenX exposure.

159 shIR) were treated with empagliflozin (10 mg/kg/d) or vehicle for 4 weeks.

160 Oral administration of NPA101.3 (10 mg/kg/day) completely prevented formation of tumors induced

161 r a 3-day course of oral azithromycin (10 mg/kg; n = 32) or placebo (n = 38).

162 ntly (P < 0.05) reduced with extract (100 mg/kg) administration and treatment compared to the hyperte

163 gliflozin was 22% greater (+0.66 +/- 0.11 mg/kg/min, P < 0.05) than in subjects receiving placebo, an

164 and model control group), metformin (120 mg/kg.bw), and PLPE (600 mg/kg.bw) by oral administration.

165 at low clinically achievable doses (0.125 mg/kg and 0.25 mg/kg) significantly protected mice against

166 zin and placebo persisted (+0.71 +/- 0.13 mg/kg/min, P < 0.01).

167 ndomized to receive isoniazid 5, 10 or 15 mg/kg daily for 7 days (inhA group), and controls with drug

168 Isoniazid 10-15 mg/kg daily had similar activity against TB strains with in

169 h followed by maintenance bevacizumab (15 mg/kg every 3 weeks in both groups) until disease progressi

170 commended phase 2 dose of margetuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks

171 ned the effect of (-)-OSU6162 (7.5 and 15 mg/kg) on oxycodone seeking on abstinence day 1 or after 15

172 six intravenous cycles of bevacizumab (15 mg/kg, day 1) plus carboplatin (area under the concentratio

173 also received intravenous daratumumab (16 mg/kg of bodyweight, once weekly during cycle one, once eve

174 usly on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycle

175 eatment with vehicle (n = 6) or 0.10-0.17 mg/kg/day of NgR1-Fc (n = 8) delivered via intrathecal lumb

176 /kg loading dose in the first week, and 2 mg/kg thereafter) for 9 weeks, starting concomitantly with

177 e: rabbit antithymocyte globulin (rATG; 2 mg/kg x 5)/rituximab (150 mg/m x 1; begun in 2013), alemtuz

178 ty, postoperative osocimab 0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/kg met criteria for noninferiority compar

179 and Agriculture Organization (FAO) of 0.2 mg/kg, whereas, all cadmium concentrations were below the l

180 loxone-methiodide at a very low dose (0.2 mg/kg; at which naloxone was undetectable in brain tissue)

181 9% (95% CI, -0.9% to infinity) at the 1.2-mg/kg dose, and 8.4% (95% CI, -2.6 to infinity) at the 1.8-

182 However, lower doses of GBP (100 and 200 mg/kg) showed no effect.

183 tudy, single dose (50, 300, 1000 and 2000 mg/kg body weight) pigment was administered to female Wista

184 outcomes between the 0.40 mg/kg and 0.25 mg/kg groups nor in all-cause deaths (26 [17%] vs 22 [15%];

185 ly achievable doses (0.125 mg/kg and 0.25 mg/kg) significantly protected mice against CDI with 100% a

186 a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cerebr

187 oes not confer an advantage over the 0.25-mg/kg dose in patients with large vessel occlusion ischemic

188 lanzapine and two were impaired after 0.3 mg/kg deschloroclozapine.

189 d NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks).

190 hether systemic CB1R antagonism (AM251; 3 mg/kg, i.p.) during memory reconsolidation altered (1) subs

191 s, the CB(2) agonist JWH133 (0.3, 1 and 3 mg/kg, IP) also produced anxiolytic-like effects in TMT-str

192 s before administering streptozotocin, 30 mg/kg body weight (T2D), and compared with age- and duratio

193 evelopment [subcutaneous injections of 30 mg/kg ketamine (KET) on postnatal days 7, 9, and 11] result

194 ng the oral rifampicin dose from 10 to 30 mg/kg, and predicted that even higher doses would further i

195 Injections of 300 mg/kg of GBP significantly increased the time spent in the

196 diets supplemented with 100, 200, and 300 mg/kg of GML, respectively.

197 MCAM (0.1-0.32 mg/kg) or the opioid receptor antagonist naltrexone (0.001-

198 nd wheat samples (glyphosate range 0.5-36 mg/kg) and comparison with the reference method (Quick Pola

199 s (max.: Arabica: 769 mg/kg, Robusta: 364 mg/kg) followed by a distinct decline.

200 phagocytic lymphohistiocytosis in the 3.4 mg/kg cohort).

201 /kg thereafter) for 18 doses or weekly (4 mg/kg loading dose in the first week, and 2 mg/kg thereafte

202 eonates (>=37 weeks gestational age) or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily therea

203 ected mice for FG2 HSA nanoparticles (0.4 mg/kg), FG 2 DMSO/saline (0.4 and 8 mg/kg) and a reference

204 rats were exposed to nicotine (0.2 or 0.4 mg/kg, subcutaneous) once daily for 7 days.

205 oncentrations were below the limit of 0.4 mg/kg.

206 he 4 functional outcomes between the 0.40 mg/kg and 0.25 mg/kg groups nor in all-cause deaths (26 [17

207 The 40 mg/kg dose resulted in 13 of 14 infants achieving the serum

208 occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not si

209 The findings suggest that the 0.40-mg/kg dose of tenecteplase does not confer an advantage ove

210 ainst TB strains with inhA mutations as 5 mg/kg against drug-sensitive strains.

211 nt related (one case of sepsis in the 2.5 mg/kg cohort and one case of haemophagocytic lymphohistiocy

212 Recipients were injected daily with 5 mg/kg cyclosporine A and received either 10 mg/kg prednisol

213 received a single ketamine infusion (0.5 mg/kg) over 40 min.

214 was further boosted to 11.5% of TSP (82.5 mg/kg) through event stacking by re-transforming the stacke

215 after an oral dose of d-amphetamine (0.5 mg/kg).

216 lowing a 40 min infusion of ketamine (0.5 mg/kg).

217 ns below the limit of quantification (0.5 mg/kg).

218 Twenty-two patients were treated at 0.5 mg/kg, and 4 DLTs occurred, including 2 irAEs and 2 with fa

219 efficacy studies, at a dose as low as 2.5 mg/kg.

220 ug-sensitive TB received standard dose (5 mg/kg/day).

221 3 or 8 weeks, then challenged with LPS (5 mg/kg; IP).

222 of cooked pork sausages produced with 50 mg/kg of sodium nitrite was investigated.

223 vo target occupancy with an EC(90) of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced a

224 mg/kg loading dose at first cycle, and 6 mg/kg thereafter) for 18 doses or weekly (4 mg/kg loading d

225 ase inhibitors plus nevirapine dosed at 6 mg/kg twice daily for term neonates (>=37 weeks gestational

226 ) or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates (34 to <3

227 arthroplasty, postoperative osocimab 0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/kg met criteria for noninferio

228 venous nerinetide in a single dose of 2.6 mg/kg, up to a maximum dose of 270 mg, on the basis of esti

229 range, 29-1200) mg/day (mean, 8.6 +/- 3.6 mg/kg/day) for a median duration of 3 (range, 0.25-18) mont

230 6% (95% CI, -1.2% to infinity) at the 0.6-mg/kg dose; 9.9% (95% CI, -0.9% to infinity) at the 1.2-mg/

231 on-matched type 1 diabetic rats (T1D) (60 mg/kg streptozotocin).

232 g concentrations ranged from 0.49 to 1.60 mg/kg w.w. and showed a significant positive relationship w

233 wley rats received monocrotaline (MCT; 60 mg/kg) or saline.

234 , metformin (120 mg/kg.bw), and PLPE (600 mg/kg.bw) by oral administration.

235 ent); ovariectomy+strontium ranelate (625 mg/kg/d) (strontium/estrogen-deficient).

236 nt), sham-surgery+strontium ranelate (625 mg/kg/d) (strontium/estrogen-sufficient); ovariectomy+stron

237 ravenous administration of ketamine (0.71 mg/kg, N=17) or the active control midazolam (0.025 mg/kg,

238 g rising HMF contents (max.: Arabica: 769 mg/kg, Robusta: 364 mg/kg) followed by a distinct decline.

239 ministered intravenously every 3 weeks (8 mg/kg loading dose at first cycle, and 6 mg/kg thereafter)

240 ve osocimab 0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/kg met criteria for noninferiority compared with enoxapa

241 (0.4 mg/kg), FG 2 DMSO/saline (0.4 and 8 mg/kg) and a reference compound, BTZ043, DMSO/saline (0.4 a

242 Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cy

243 compound, BTZ043, DMSO/saline (0.4 and 8 mg/kg).

244 a obtained pre- and post-TCZ treatment (8 mg/kg, 6x, monthly) from 12 cAMR patients who failed standa

245 with enoxaparin, and the preoperative 1.8-mg/kg dose of osocimab met criteria for superiority compare

246 .4% (95% CI, -2.6 to infinity) at the 1.8-mg/kg dose.

247 infusion of the same n-apo AI (CSL111, 80 mg/kg) similarly reduced the level of circulating leukocyte

248 1/2) > 145 min and CL(int(mic)) < 9.6 mL/min/kg).

249 Blood volume (mL kg(-1) ) and LV mass index (g m(-2) ) were larger in OT

250 Peak Vo(2) (13.1+/-3.4 versus 22.7+/-4.0 mL/kg/min; P<0.001) and heart rate (122+/-20 versus 155+/-1

251 An intravenous injection of 1.5 ml/kg of body mass of non-ionic contrast agent was performe

252 ing an intravenous contrast bolus (0.05 mmol/kg, gadobutrol).

253 or 0.74 mol/kg fructose and 0.17 or 0.19 mol/kg lactose with an enzymatic activity of 2.0 or 2.8 muka

254 lactulose was determined as 1.28 or 0.74 mol/kg fructose and 0.17 or 0.19 mol/kg lactose with an enzy

255 PFOS precursor SAmPAP diester (max 1 872 mug kg(-1)).

256 ision limit (CCalpha) ranged 0.028-0.182 mug.kg(-1) and capability of detection limit (CCbeta) ranged

257 the rest of the substances were 0.1-14.1 mug/kg with a precision of 1.9-23.0% in 10% ethanol and were

258 9-23.0% in 10% ethanol and were 0.1-20.2 mug/kg with a precision of 2.5-19.6% in 3% acetic acid simul

259 were exposed to the vehicle or 20 or 200 mug/kg/day of DEHP from gestation day 11 until birth.

260 ed fashion, using statistical models, 25 mug/kg BW/d BPA [BPA(25)], or 250 mug/kg BW/d BPA [BPA(250)]

261 re of rats to low-dose BPA at 25 and 250 mug/kg BW/d altered the estrous cycle and uterine pathology

262 ls, 25 mug/kg BW/d BPA [BPA(25)], or 250 mug/kg BW/d BPA [BPA(250)] exerted effects similar to that o

263 ed effects similar to that of EE2 at 0.5 mug/kg BW/d in 1-y-old rats.

264 or perinatally exposed to a low dose (54 mug/kg/d) of PCB-153.

265 th an enzymatic activity of 2.0 or 2.8 mukat/kg for acid (pH 4.4) or sweet (pH 6.6) whey.

266 fter a single dose of the ADC-46 (0.02 mumol/kg).

267 -3) and in the sediment from 239 to 13 331 N kg(-1).

268 0(3), 6.0-4.5 x 10(3), and 15-3.0 x 10(3) ng kg(-1) and limits of detection of 1.37 +/- 0.10, 4.7 +/-

269 7 +/- 0.10, 4.7 +/- 1.2, and 10.1 +/- 5.7 ng kg(-1) were obtained, respectively.

270 2), 59.19 (95% CI: 51.84-66.54) and 35.23 ng/kg (95% CI: 31.53-38.92), considering 4, 55 and 18 TLC,

271 which were the highest in northern (88.77 ng/kg).

272 he mean of AFM1 levels was obtained 55.97 ng/kg (95% CI: 50.09-61.84).

273 or particles greater than 0.355 mm of 65.2 p kg(-1) in Lake Michigan samples (n = 20) and 431 p kg(-1

274 in Lake Michigan samples (n = 20) and 431 p kg(-1) in Lake Erie samples (n = 12).

275 infusion (cohort A), or 2 x 10(6) cells per kg body weight, to a maximum dose of 2 x 10(8) cells per

276 t a dose level of either 1 x 10(6) cells per kg body weight, to a maximum of 1 x 10(8) cells per infu

277 increased it to 2.7 +/- 0.2 kg CO(2) eq per kg milk because of land use change emissions.

278 m 2.4 +/- 0.1 to 1.6 +/- 0.1 kg CO(2) eq per kg milk, FeCo reduced it to 2.2 +/- 0.1, whereas FoFeCo

279 dependency on animal-source feed inputs per kg of fillet.

280 Median exposure (dose area product/kg) was decreased by 30% for all procedures.

281 a product per body weight (dose area product/kg; uGy*m(2)/kg) and reported by expected radiation expo

282 ion to high protein intake (>2.1 g protein . kg LBM-1 . d-1) led to a significantly higher net protei

283 160 muM and accumulated up to 1300 mg of Se/kg shoot dry weight.

284 tructure was altered when mTG exceeded 100 U.kg(-1), determined by confocal microscopy, extractabilit

285 ocid, 15 ug kg(-1) for nicarbazin and 120 ug kg(-1) for diclazuril.

286 mples were 20 ug kg(-1) for lasalocid, 15 ug kg(-1) for nicarbazin and 120 ug kg(-1) for diclazuril.

287 n calculated on fortified samples were 20 ug kg(-1) for lasalocid, 15 ug kg(-1) for nicarbazin and 12

288 was lower than the benchmark level of 400 ug kg(-1) for roast coffee set by the EU Commission Regulat

289 tection limit (CCbeta) ranged 0.032-0.233 ug.kg(-1).

290 ure levels (concentration range: 209-1119 ug/kg).

291 Cebranopadol at a low dose of 25 ug/kg (p.o.) did not induce significant hyperactivity itsel

292 4.9, 242.2, 298.5, 230.7, 253.4 and 293.5 ug/kg, respectively.

293 d granulocyte-colony stimulating factor 5 ug/kg/dose, days 1-5 and day 15 through absolute neutrophil

294 However, when infusion rates exceeded 20 ul/kg/min, signs of injury occurred at pressures from 0.39

295 pplying constant microwave (MW) power (167 W/kg) and pulsed MW power (500 and 667 W/kg with 10 s puls

296 muscles develop high net power (134 +/- 20 W/kg at 80 Hz) in cyclical work loop experiments designed

297 sulting in an average power of 167 and 222 W/kg) during the freezing process.

298 167 W/kg) and pulsed MW power (500 and 667 W/kg with 10 s pulse width and 20 s pulse interval resulti

299 kg(-1) and an energy density of up to 73 Wh kg(-1) , which are comparable to several commercial devi

300 -1) ), large specific energy density (775 Wh kg(-1) ), and good cycling stability.